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INNOVATIONS INHEALTHCAREDELIVERY
Does the Country of OriginMatter
in Health Care Innovation Diffusion?
There is no shortage of US health care research cen-
ters advocating the adoptionof innovations fromother
countries. The Institute for Healthcare Improvement
(Boston,MA), theCommonwealthFund(NewYork,NY),
Innovations inHealth atDukeUniversity (Durham,NC),
and the Network for Excellence in Healthcare Innova-
tion (Cambridge,MA)areallpromoting innovations from
low-, middle-, and high-income countries for potential
adoption into the United States. However, does it mat-
ter to patients if a proposed innovation is from India,
rather than from, say, Sweden; or from Rwanda, rather
than from, say, theUnitedKingdom?Very little is known
about whether and how the country of origin of a pro-
posed innovationmatters in its diffusion.
Thequestionof countryof originmatters consider-
ably to those in themarketing industry. Research span-
ningseveraldecadeshasshownthatupto30%ofacon-
sumer’s attitude towardaproduct canbe influencedby
the country of origin of that product.1 There is a com-
plex interaction among the product type, where it is
from, where the consumer is from, the demographic
characteristics of the consumer, and the geopolitical
characteristics of the 2 countries. For example, prod-
ucts fromEngland tend tobe ratedhigherby Indian stu-
dents than by Taiwanese students because of the colo-
nial ties between India and England. White consumers
tend to rate products from North America more highly
thannonwhite consumers,who instead ratedproducts
fromNigeria, LatinAmerica, and Indiamorehighly.Com-
plex as this interaction is, it is also likely to change over
time as preferences, political ties, and cultures con-
stantly shift and change as well.
The diffusion of innovation literature in health care
is silent on the issue. Rogers2 limits his diffusion of in-
novation theory only to the characteristics of the
adopter.Greenhalghetal3 incorporatecharacteristicsof
theadoptingorganization, of the innovation, andof the
change process but not of the source. Damschroder
et al4 adds to the model of Greenhalgh et al and refers
to the source of the innovation needing to be “legiti-
mate” but sheds little light on what constitutes legiti-
mate, forwhom,andunderwhat circumstances. In their
international study of the cultural dynamics to support
innovation diffusion, Keownet al5 note the importance
of empowering patients, engaging health care profes-
sionals, promoting learning, refining the innovation, and
eliminating legacy practices, but again, say little on the
effect of the source of an innovation.
None of thesemodels or theories refers to the role
of the adopters’ perception of the innovator source as
amediating factor in theadoptionof an innovation. This
is perhaps because such perception does not fit neatly
into current conceptualizations of mediating factors in
innovation diffusion; ie, is it a feature of the innovation,
of the adopter, or of both?
The paucity of research in this area could lead to
the assumption that even though country of origin
matters when choosing to purchase products such as a
car or some foods, it does not apparently matter when
choosing whether to pilot a health care innovation as
long as the innovation has been approved by the
adopting country’s regulatory body. The reality is that
the effect that sourcemay have on the perception of an
innovation is simply a neglected and yet
potentially considerably significant
issue for health care practitioners and
organizations as well as recipients of
health care. Some evidence suggests
that the country of origin matters in
research evaluation and publication. A
recent randomized trial showed that
a source from a low-income country
negatively influencedUS public health professors’ opin-
ion of research abstracts in some instances.6 Partici-
pants (n = 899) were more likely to refer 1 abstract of
the 4 abstracts that were included in the trial to a peer
if the source was from a high-income country com-
paredwith a low-income country (odds ratio, 1.28; 95%
CI, 1.02-1.62). Although the effect size was small under
experimental conditions, it may be “clinically” signifi-
cant considering how much research is published and
consumed on a daily basis. This study established a
benchmark with respect to the measurable effect of
source on research interpretation and evaluation but
needs to be repeated using different types of health
care professionals and different types of research
abstracts as well as the relationship between percep-
tion of research and of innovation.
The so-called reverse innovation process—the
adoption of low-income country innovations into
high-income country contexts—is thwarted in part by
perceptions that low-income countries are unlikely to
offer innovations of value and that these contexts are
More research is needed to understand
the effect of source in interpretation of
health care research and in the appetite
to learn from other countries.
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“too different” from their own for the innovation to “fit.”7 This will
lead to missed opportunities to learn from many exciting innova-
tions arising from these contexts in areas as diverse as cardiac sur-
gery, ophthalmic surgery, community health, mobile phone screen-
ing apps, diagnostic support tools, and ambulatory services. For
example, Narayana and Aravind are widely acclaimed Indian health
care models in cardiac and ophthalmic surgery, respectively, yet
they have not successfully diffused into more developed markets.
The Brazilian Family Health Strategy systematically deploys more
than 250000 community health workers to provide cradle-to-
grave health advice, universally, through home visits. Peek Vision is
amobile phone–based tool for retinography imaging used in Kenya.
Ziqitza uses a novel cost-sharing finance model to provide ambu-
lance services to poor communities in India.
Understandably, most innovations must be incorporated into
delivery systems, and how health care is financed, organized, and
delivered varies from country to country. Adoption processes are
likely tobedifferent for services andproducts.However, given that
no two, even neighboring, contexts are the same, differential pref-
erence for innovations from one country as opposed to another
speaks tobiases rather thanobjectiveassessmentsof reality. To this
extent,methodsfromthecognitivepsychology literaturecanbeused
to examine further assumptions, biases, and prejudices8 concern-
inghowtodeterminewhat is andwhat isnotgeneralizable fromone
context to another.
More research is needed to better understand the effect of
source in interpretation of health care research and in the appetite
to learn from other countries. It is time to establish a comprehen-
sive researchagenda that applies theknowledgeandmethods from
the marketing and consumer affairs literatures to the assessment
of health care research and innovation. Just as themarketing litera-
ture examines the effect of the phrase “Made in [country],” re-
search into theeffect of thephrase “Authors’ affiliation” inbiomedi-
cal research is needed. It is important to know, using adequately
powered, controlled studies, whether research from certain insti-
tutions has been given less attention and credibility than fromoth-
ers, all other thingsbeingequal. Itmustbeclear if thepowerfulbrand
associated with high-impact journals influences readers’ percep-
tions of the research, all things being equal. The relative impor-
tanceofwheretheresearchwasconductedcomparedwithwhocon-
ducted it and where it was published needs to be clarified. For
example, what is the relative importance of bibliometric or scien-
tometric markers of legitimacy, such as citation indices, to organi-
zationalmarkers of legitimacy such as university rankings, to socio-
economic measures of legitimacy, such as gross domestic product
per capita, Human Development Index, infant mortality rates, and
Gini Index?
In addition, the interactionsbetween these characteristics and
those of the “consumer” (the health care professional or equiva-
lent) and the “product” (the researcharticleor the innovation)need
tobeassessed.Usingadequatelypowered, controlled studies, how
is the source of a research article or innovation affected by the age,
sex, race,andacademic, clinical, ormanagerial experienceof theper-
son reviewing it, and howdoes this changebased on the type of in-
novation—technological innovations, service delivery innovations,
or pharmaceutical interventions? For example, are US health care
managers more amenable to adopting technological innovations
from the United Kingdom than US clinicians? Is this the case if the
innovation is from Sweden or Rwanda, or if it is a service delivery
innovation? Does it matter if the innovation is published in a high-
impact,widelydisseminated, generalmedical journal (suchas JAMA
or theNew England Journal of Medicine) or a more focused journal
(such as the Scandinavian Journal of Public Health)?
Significant resources are allocated to better understand the
influence of country of origin for consumers. Advertising agencies
go to great lengths to develop counterstereotyping and stereotyp-
ing campaigns and to create effective brands that build on
(or, indeed, minimize) the image of the source country. It is why it is
acceptable to perceive that cars from Japan are efficient, chocolate
from Switzerland is delicious, and perfume from France is of
high quality. A consumermight have considerably different percep-
tions of cars, chocolate, and perfume if those products were from
Ethiopia, Botswana, and India, respectively. These stereotypes are
enduring and well managed through the long-standing efforts of
manufacturers and advertisers.
It is time to examine much more closely how these prefer-
ences affect the evaluation of research and influence the diffusion
of health care innovations.
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